Literature DB >> 26365317

Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration.

Joung-Woo Choi1, Kasala Dayananda1, Soo-Jung Jung1, Soo-Hwan Lee1, Donghyun Kim2, Jun Hu3, You Han Bae4, Chae-Ok Yun5.   

Abstract

Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intravenously administered Ad may encounter difficulties due to unfavorable host responses, non-specific interactions, and the heterogeneity of the tumor cell population. As an approach to combine the advantages of oncolytic Ad and synthetic polymers and to address the associated difficulties, Ad was physically complexed with a pH-sensitive block copolymer, methoxy poly(ethylene glycol)-b-poly(l-histidine) (mPEG-b-pHis). The in vitro transduction efficiency at an acidic extracellular pH was remarkably enhanced in cancer cells when treated with the Ad expressing green fluorescent protein (GFP) coated with mPEG-b-pHis (c-dE1/GFP) as compared to that of naked Ad (n-dE1/GFP). Time-lapse total internal reflection fluorescence microscopic imaging revealed a significantly enhanced cellular uptake rate of c-dE1/GFP at acidic tumor pH when compared with that at neutral pH or naked cognate Ad (n-dE1/GFP). In addition, c-dE1/GFP remained relatively stable in human serum-containing media, and considerably reduced both the innate and adaptive immune response against Ad. Moreover, the therapeutic efficacy and survival benefit of mPEG-b-pHis-complexed oncolytic Ad (c-H5mT/Luc) by systemic treatment was significantly enhanced compared to that with naked oncolytic Ad (n-H5mT/Luc) in both coxsackie and adenovirus receptor-positive and -negative tumors. Whole-body bioluminescence imaging showed 7.3-fold higher luciferase expression at the tumor site and 23.0-fold less luciferase expression in liver tissue for c-H5mT/Luc relative to that for naked oncolytic Ad (n-H5mT/Luc). Considering the heterogeneity of tumor tissue, these results are important for guiding the development of more potent and specific treatment of devastating metastatic cancers using this viral system. STATEMENT OF SIGNIFICANCE: Although adenoviral systems have shown considerable promise and undergone extensive evaluation attempts to specifically target Ad vectors to cancer cells have met limited success. This shortcoming is due to the strong immune response stimulated by Ad and the hepatotoxicity of the viral particles. To overcome restricted vector issues, we generated Ad/mPEG-b-pHis for tumor microenvironment-targeting hybrid vector systems, an oncolytic Ad coated with a pH-responsive polymer, mPEG-b-pHis. The Ad/mPEG-b-pHis exhibited pH-dependent transduction efficiency and cancer-cell killing effects. Moreover, systemic administration of oncolytic Ad/mPEG-b-pHis led to marked suppression of tumor growth and tumor-specific viral replication. Ad successfully avoided the innate and adaptive immune responses and liver accumulation with the help of mPEG-b-pHis on its surface.
Copyright © 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer gene therapy; Oncolytic adenovirus; Systemic administration; pH-sensitive polymers

Mesh:

Year:  2015        PMID: 26365317     DOI: 10.1016/j.actbio.2015.09.014

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  3 in total

Review 1.  Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.

Authors:  Binlong Chen; Wenbing Dai; Bing He; Hua Zhang; Xueqing Wang; Yiguang Wang; Qiang Zhang
Journal:  Theranostics       Date:  2017-01-07       Impact factor: 11.556

Review 2.  Therapeutic Targeting of Neutrophil Granulocytes in Inflammatory Liver Disease.

Authors:  Matthias Bartneck; Jing Wang
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

Review 3.  Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses.

Authors:  Thavasyappan Thambi; JinWoo Hong; A-Rum Yoon; Chae-Ok Yun
Journal:  Cancer Gene Ther       Date:  2022-04-20       Impact factor: 5.854

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.